Volunteer Assignments and Opportunities: Difference between revisions
Snehal.Patel (talk | contribs) No edit summary |
Snehal.Patel (talk | contribs) No edit summary |
||
| (55 intermediate revisions by 5 users not shown) | |||
| Line 71: | Line 71: | ||
|- | |- | ||
| Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease | | Chronic Eosinophilic Leukemia, Not Otherwise Specified||Disease | ||
|(trainee), Daynna J.Wolff | |(trainee), Daynna J.Wolff | ||
| | | | ||
| | | | ||
| | |pending faculty review | ||
| | | | ||
|FQR | |FQR | ||
| Line 99: | Line 99: | ||
|- | |- | ||
| Cutaneous Mastocytosis||Disease | | Cutaneous Mastocytosis||Disease | ||
|Thuy Phung | |Thuy Phung/Shuo-Shawn Liu | ||
| | | | ||
| | | | ||
|complete/pending adding content online as of 2/4/21 | |||
| | | | ||
|FQR | |FQR | ||
| Line 121: | Line 121: | ||
|Thuy Phung +Jordan Lowery | |Thuy Phung +Jordan Lowery | ||
| | | | ||
| | | | ||
|complete | |complete | ||
| | | | ||
| Line 344: | Line 344: | ||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
| | |04/26/2021 -MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 352: | Line 352: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |03/01/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 360: | Line 360: | ||
|PENDING | |PENDING | ||
| ||JH / MS | | ||JH / MS | ||
| | |04/26/2021 -MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 366: | Line 366: | ||
| | | | ||
| | | | ||
| | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |03/01/2021-MS | ||
| | | | ||
|- | |- | ||
| Line 374: | Line 374: | ||
| | | | ||
| | | | ||
| | |Complete | ||
| ||JH / MS | |02/03/2021||JH / MS | ||
| | | | ||
| | | | ||
| Line 382: | Line 382: | ||
| | | | ||
| | | | ||
| | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |03/02/2021-MS | ||
| | | | ||
|- | |- | ||
| Line 392: | Line 392: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |03/02/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 400: | Line 400: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |04/26/2021 -MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 409: | Line 409: | ||
| | | | ||
|JH / MS | |JH / MS | ||
| | |03/01/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 417: | Line 417: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |04/26/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 425: | Line 425: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |03/01/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 433: | Line 433: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |03/01/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 441: | Line 441: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |03/01/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 449: | Line 449: | ||
|Complete | |Complete | ||
| ||JH / MS | | ||JH / MS | ||
| | |02/24/2021-MS (re-review) | ||
| | | | ||
|- | |- | ||
| Line 684: | Line 684: | ||
| | | | ||
|- | |- | ||
| Mixed-Phenotype Acute | | Mixed-Phenotype Acute Leukemia, Not Otherwise Specified (NOS), Rare Types||Disease||Daynna Wolff+ Elicia Goodale (resident) | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| ||JH / MS | | ||JH / MS | ||
| | | | ||
| | | | ||
|- | |- | ||
| Acute | | Acute Leukemias of Ambiguous Lineage, Not Otherwise Specified (NOS)||Disease||Daynna Wolff+Madison Hannay or Elicia Goodale (residents) | ||
| | | | ||
| | | | ||
| | |PENDING | ||
| ||JH / MS | | ||JH / MS | ||
| | | | ||
| Line 834: | Line 834: | ||
| | | | ||
|- | |- | ||
| B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease|| | | B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified||Disease||Holli Drendel | ||
| | | | ||
| | | | ||
|PENDING | |||
| ||YA | | ||YA | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 | ||
|Disease | |||
|Diana Rush | |||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|YA | |||
| | | | ||
|NON-WHO ENTITY | |||
|- | |- | ||
| | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 | ||
|Disease | |||
|Celeste Eno | |||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|YA | |||
| | | | ||
|NON-WHO ENTITY | |||
|- | |- | ||
| | |B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements | ||
|Disease | |||
|Marilena Melas | |||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|YA | |||
| | | | ||
|NON-WHO ENTITY | |||
|- | |- | ||
|B-Lymphoblastic Leukemia/Lymphoma with | |B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions | ||
|Disease | |Disease | ||
| | |Chenkai Ma | ||
| | | | ||
| | | | ||
| Line 877: | Line 886: | ||
|NON-WHO ENTITY | |NON-WHO ENTITY | ||
|- | |- | ||
| || | |B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) | ||
|Disease | |||
|Celeste Eno | |||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |YA | ||
| | | | ||
|NON-WHO ENTITY | |||
|- | |- | ||
| | |B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11) | ||
|Disease | |||
|Alaa Koleilat | |||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |YA | ||
| | | | ||
|NON-WHO ENTITY | |||
|- | |- | ||
| | |'''''T-Lymphoblastic Leukemia/Lymphoma'''''||'''''Overview'''''||Fei Yang | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | ||YA | ||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Early T-Cell Precursor Lymphoblastic Leukemia||Disease||Fei Yang | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | ||YA | ||
| | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |NK-Lymphoblastic Leukemia/Lymphoma||Disease||Fei Yang | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| ||YA | |||
| | | | ||
| | | | ||
|- | |||
| || || | |||
| | | | ||
| | | | ||
| | | | ||
| | | || | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''Mature B-Cell Neoplasms'''''||'''''Overview'''''|| | ||
| | |||
| | | | ||
| | | | ||
| | | ||Snehal Patel (SP) | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|SP | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Monoclonal B-cell Lymphocytosis||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|SP | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |B-cell Prolymphocytic Leukemia||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|SP | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Splenic Marginal Zone Lymphoma||Disease||Snehal Patel | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | | | ||
|SP | |SP | ||
| Line 974: | Line 984: | ||
| | | | ||
|- | |- | ||
| | |Hairy Cell Leukemia||Disease||Snehal Patel | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | | | ||
|SP | |SP | ||
| Line 983: | Line 993: | ||
| | | | ||
|- | |- | ||
| | |'''''Splenic B-cell Lymphoma/Leukemia, Unclassifiable'''''||'''''Overview'''''||Snehal Patel | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Splenic Diffuse Red Pulp Small B-cell Lymphoma||Disease||Snehal Patel | ||
| | | | ||
| | | | ||
|Complete | |||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Hairy Cell Leukemia Variant||Disease||Snehal Patel | ||
| | | | ||
| | | | ||
|Complete | |||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Lymphoplasmacytic Lymphoma||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Waldenstrom Macroglobulinemia||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |IgM Monoclonal Gammopathy of Undetermined Significance||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''Heavy Chain Diseases'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Mu Heavy Chain Disease||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Gamma Heavy Chain Disease||Disease||Manisha Sutariya | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | |5/26/2021||SP | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Alpha Heavy Chain Disease||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Plasma Cell Neoplasms||'''''Overview'''''||Zhenya Tang | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Non-IgM Monoclonal Gammopathy of Undetermined Significance||Disease||Zhenya Tang | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Plasma Cell Myeloma||Disease||Zhenya Tang/Huang Mo (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Plasma Cell Myeloma Variants||Disease||Fariborz Rashid-Kolvear | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Plasmacytoma||Disease||Zhenya Tang | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |''''' Monoclonal Immunoglobulin Deposition Diseases'''''||'''''Overview'''''|| | ||
| | | | ||
| | | | ||
| Line 1,116: | Line 1,131: | ||
| | | | ||
|- | |- | ||
| | | Primary Amyloidosis||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Light Chain and Heavy Chain Deposition Disease||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| ||SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |'''''Plasma Cell Neoplasms with Associated Paraneoplastic Syndrome'''''||'''''Overview'''''|| | ||
| | |||
| | | | ||
| | | | ||
| | | ||SP | ||
| | |||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | POEMS Syndrome||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | TEMPI Syndrome||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
|SP | | ||SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)||Disease||Whayoung Lee, trainee)/Fabiola Quintero-Rivera | ||
| | |3/9/21 | ||
| | | | ||
|PENDING | |PENDING | ||
| Line 1,169: | Line 1,180: | ||
| | | | ||
|- | |- | ||
| | |Nodal Marginal Zone Lymphoma||Disease||Shivani Golem | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | |5/28/2021||SP | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
|Paediatric | | Paediatric Nodal Marginal Zone Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | ||
| | | | ||
| | | | ||
|Complete | |Complete | ||
| | |11/11/2020 | ||
|SP | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Follicular Lymphoma||Disease||Ruthann Pfau | ||
| | |||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | Testicular Follicular Lymphoma||Disease||Ruthann Pfau | ||
| | | | ||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
|SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | | In Situ Follicular Neoplasia||Disease||Ruthann Pfau | ||
| | |||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
| Line 1,212: | Line 1,224: | ||
| | | | ||
|- | |- | ||
| | | Duodenal-Type Follicular Lymphoma||Disease||Ruthann Pfau | ||
| | |||
| | | | ||
|PENDING | |PENDING | ||
| | | | ||
| Line 1,221: | Line 1,233: | ||
| | | | ||
|- | |- | ||
| | |Paediatric-Type Follicular Lymphoma||Disease||Ruthann Pfau, Kathleen Schieffer (trainee) | ||
| | | | ||
| | | | ||
|Complete | |||
|8/16/2020 | |||
|SP | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| || || | |Large B-cell Lymphoma with IRF4 Rearrangement||Disease||Afia Hasnaid | ||
| | | | ||
|9/30/20 | |||
|Complete | |||
|5/26/2021||SP | |||
| | | | ||
| | | | ||
| || | |- | ||
|Primary Cutaneous Follicle Centre Lymphoma||Disease||Shivani Golem | |||
| | |||
| | |||
|PENDING | |||
| ||SP | |||
| | | | ||
| | | | ||
|- | |- | ||
| | |Mantle Cell Lymphoma||Disease||Mahsa Khanlari | ||
| | | | ||
|8/15/20 | |||
|PENDING | |PENDING | ||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | Leukemic Non-Nodal Mantle Cell Lymphoma||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | In Situ Mantle Cell Neoplasia||Disease|| | ||
| | |||
| | | | ||
| | | | ||
| | | | ||
| | |SP | ||
| | | | ||
| | | | ||
|- | |- | ||
| | | || || | ||
| | | | ||
| | | | ||
| | | | ||
| || | | || | ||
| | | | ||
| | | | ||
|- | |- | ||
| | |Diffuse Large B-cell Lymphoma, Not Otherwise Specified||Disease||Ashwini Yenamandra | ||
| | | | ||
| | | | ||
|PENDING | |||
| | | | ||
| | |Greg Corboy (GC) | ||
| | | | ||
| | | | ||
|- | |- | ||
|EBV-Positive Mucocutaneous Ulcer||Disease|| | |T-cell/Histiocyte-Rich Large B-cell Lymphoma||Disease|| | ||
| | |||
| | |||
| | |||
| ||GC | |||
| | |||
| | |||
|- | |||
|Primary Diffuse Large B-cell Lymphoma of the CNS||Disease|| | |||
| | |||
| | |||
| | |||
| ||GC | |||
| | |||
| | |||
|- | |||
|Primary Cutaneous Diffuse Large B-cell Lymphoma, Leg Type||Disease|| | |||
| | |||
| | |||
| | |||
| ||GC | |||
| | |||
| | |||
|- | |||
|EBV-Positive Diffuse Large B-cell Lymphoma, Not Otherwise Specified (NOS)||Disease|| | |||
| | |||
| | |||
| | |||
| ||GC | |||
| | |||
| | |||
|- | |||
|EBV-Positive Mucocutaneous Ulcer||Disease|| | |||
| | | | ||
| | | | ||
| Line 1,383: | Line 1,438: | ||
| | | | ||
|- | |- | ||
|Burkitt Lymphoma||Disease|| | |Burkitt Lymphoma||Disease||Becky Leung (trainee), Greg Corboy | ||
| | |3/11/21 | ||
| | | | ||
|PENDING | |||
| ||GC | | ||GC | ||
| | | | ||
| Line 1,487: | Line 1,542: | ||
| | | | ||
|- | |- | ||
| Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease|| | | Systemic EBV-Positive T-cell Lymphoma of Childhood||Disease||Lisa Lansdon (trainee) | ||
| | | | ||
| | | | ||
| Line 1,547: | Line 1,602: | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | |1/21/2021 | ||
|SP | |SP | ||
| | | | ||
| Line 1,583: | Line 1,638: | ||
| | | | ||
| | | | ||
| | |Complete | ||
| | |1/21/2021 | ||
|SP | |||
| | | | ||
| | | | ||
| Line 1,604: | Line 1,660: | ||
| | | | ||
|- | |- | ||
|Sézary Syndrome||Disease|| | |Sézary Syndrome||Disease||Daynna Wolff, Madison Hannay (trainee) | ||
| | | | ||
| | | | ||
|PENDING | |||
| ||SP | | ||SP | ||
| | | | ||
| Line 1,757: | Line 1,813: | ||
| | | | ||
| | | | ||
| || | | ||Greg Corboy (GC) | ||
| | | | ||
| | | | ||
| Line 1,765: | Line 1,821: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,773: | Line 1,829: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,781: | Line 1,837: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,789: | Line 1,845: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,797: | Line 1,853: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,805: | Line 1,861: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,813: | Line 1,869: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,821: | Line 1,877: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,829: | Line 1,885: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,837: | Line 1,893: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,848: | Line 1,904: | ||
|PENDING | |PENDING | ||
| | | | ||
| | |GC | ||
| | | | ||
| | | | ||
| Line 1,856: | Line 1,912: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,864: | Line 1,920: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,872: | Line 1,928: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,880: | Line 1,936: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,888: | Line 1,944: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,896: | Line 1,952: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,904: | Line 1,960: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,912: | Line 1,968: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,920: | Line 1,976: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,928: | Line 1,984: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,936: | Line 1,992: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,944: | Line 2,000: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 1,952: | Line 2,008: | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
| Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| | | Inflammatory Pseudotumor-Like Follicular/Fibroblastic Dendritic Cell Sarcoma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
|Fibroblastic Reticular Cell Tumor||Disease|| | |Fibroblastic Reticular Cell Tumor||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
|Disseminated Juvenile Xanthogranuloma||Disease|| | |Disseminated Juvenile Xanthogranuloma||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
|- | |- | ||
|Erdheim-Chester Disease||Disease|| | |Erdheim-Chester Disease||Disease|| | ||
| | | | ||
| | | | ||
| | | | ||
| || | | ||GC | ||
| | | | ||
| | | | ||
| Line 2,700: | Line 2,756: | ||
| | | | ||
|- | |- | ||
| | |BRCA1 | ||
| | | | ||
| | | | ||
| Line 2,710: | Line 2,766: | ||
| | | | ||
|- | |- | ||
| | |BRCA2 | ||
| | | | ||
| | | | ||